None listed
Conditions
Brief summary
The primary aim of this study is to investigate the effect that a viscous fibre supplement, PGX, has on frequency of eating occasions in overweight adults, over a 12-week period. In addition to this, body weight, waist circumference, blood pressure and fasting venous blood samples will be measured both at baseline and post-intervention. The blood samples will be used to measure glucose, insulin, changes in insulin sensitivity, triglycerides, cholestrol (total, HDL and LDL) and apoB48. Eating occasions will be recorded using a mobile device food record and automatically uploaded to a server for analysis. It is hypothesised that the fibre supplement will reduce the frequency of eating occasions, leading to a subsequent reduction in body weight. OBJECTIVES 1. To investigate the effect of a viscous fibre supplement on frequency of eating occasions in overweight adults, over a 12-week period. 2. To measure body weight, waist circumference, blood pressure and fasting venous blood samples differences between baseline and at the end of the 12-week intervention. Aim 1. To investigate the effect of a viscous fibre supplement has on frequency of eating occasions in overweight adults Hypothesis Overweight adults receiving the viscous soluble fibre (PGX) will significantly reduce their intake of energy-dense nutrient poor foods and number of eating occasions compared with controls
Interventions
Sponsors
Study design
Eligibility
Inclusion criteria
Overweight as defined by a body weight index (BMI) of 25 – 29 kg/m2 and not under current medical supervision
Exclusion criteria
Subjects will be excluded if (a) pregnant; (b) unable to complete the 12 week study; (c) undertake extreme forms of exercise or dieting; or (d) unable to attend the study centre on four occasions (two at baseline for satiety training and dietary training and for fasting blood, weight height and waist circumference and final visit at 12 weeks; e) are smokers; f) have an allergy to any food ingredients used in the study; g) current use of lipid-lowering or antihypertensive drugs, insulin injection use; h) renal, liver or respiratory failure; i) previous gastric or weight-loss surgery; j) any malabsorptive conditions and current or recent dietary fibre supplementation. Subjects must be weight stable – i.e. weight fluctuations not greater than +/- 5 kg in last 12 months. Subject will not be restrained eater on entry to the study.